Assetmark Inc buys $8,834,623 stake in Amgen (AMGN)

Amgen (AMGN) : Assetmark Inc scooped up 6,409 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 51,236 shares of Amgen which is valued at $8,834,623.Amgen makes up approximately 0.14% of Assetmark Inc’s portfolio.

Other Hedge Funds, Including , Schnieders Capital Management boosted its stake in AMGN in the latest quarter, The investment management firm added 350 additional shares and now holds a total of 18,400 shares of Amgen which is valued at $3,172,712. Amgen makes up approx 1.74% of Schnieders Capital Management’s portfolio.Institutional Family Asset Management boosted its stake in AMGN in the latest quarter, The investment management firm added 190 additional shares and now holds a total of 5,349 shares of Amgen which is valued at $928,907. Amgen makes up approx 0.32% of Institutional Family Asset Management’s portfolio.Pillar Pacific Capital Management boosted its stake in AMGN in the latest quarter, The investment management firm added 2,616 additional shares and now holds a total of 53,138 shares of Amgen which is valued at $9,215,723. Amgen makes up approx 1.48% of Pillar Pacific Capital Management’s portfolio.W.g. Shaheen Associates Dba Whitney Co boosted its stake in AMGN in the latest quarter, The investment management firm added 363 additional shares and now holds a total of 15,885 shares of Amgen which is valued at $2,631,668. Amgen makes up approx 1.04% of W.g. Shaheen Associates Dba Whitney Co’s portfolio.Pioneer Trust Bank N Aor boosted its stake in AMGN in the latest quarter, The investment management firm added 1,545 additional shares and now holds a total of 19,345 shares of Amgen which is valued at $3,151,881. Amgen makes up approx 1.86% of Pioneer Trust Bank N Aor’s portfolio.

Amgen opened for trading at $171.48 and hit $174.72 on the upside on Monday, eventually ending the session at $174.58, with a gain of 0.90% or 1.56 points. The heightened volatility saw the trading volume jump to 27,84,334 shares. Company has a market cap of $130,649 M.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *